

Accepted Manuscript

Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Maria Diletta Pezzani, Valentina Di Cristo, Carlo Parravicini, Angelica Sonzogni, Marco Franzetti, Salvatore Sollima, Mario Corbellino, Massimo Galli, Laura Milazzo, Spinello Antinori

PII: S1477-8939(19)30009-2

DOI: <https://doi.org/10.1016/j.tmaid.2019.01.013>

Reference: TMAID 1378

To appear in: *Travel Medicine and Infectious Disease*


Received Date: 21 June 2018

Revised Date: 18 December 2018

Accepted Date: 16 January 2019

Please cite this article as: Pezzani MD, Di Cristo V, Parravicini C, Sonzogni A, Franzetti M, Sollima S, Corbellino M, Galli M, Milazzo L, Antinori S, Gastrointestinal basidiobolomycosis: An emerging mycosis difficult to diagnose but curable. Case report and review of the literature, *Travel Medicine and Infectious Disease* (2019), doi: <https://doi.org/10.1016/j.tmaid.2019.01.013>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TMAID-D-18-00147R1

Gastrointestinal basidiobolomycosis: an emerging mycosis difficult to diagnose but curable. Case report and review of the literature

Maria Diletta Pezzani ^{1*§}, Valentina Di Cristo ^{1*}, Carlo Parravicini ², Angelica Sonzogni ³, Marco Franzetti ^{4^}, Salvatore Sollima ⁴, Mario Corbellino ⁴, Massimo Galli ^{1,4}, Laura Milazzo ⁴, Spinello Antinori ^{1,4}

¹Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milano, Italy;

²Institute of Pathology, Luigi Sacco Hospital, Milano, Italy; ³Division of Pathology, Istituto Europeo di Oncologia, Milano, Italy; ⁴ III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Ospedale L Sacco, Milano, Italy

Correspondence to :

Prof Spinello Antinori

Department of Biomedical and Clinical Sciences Luigi Sacco,

University of Milano, Italy

Tel 00390250319765

Email: spinello.antinori@unimi.it

Key words : Basidiobolomycosis ; gastrointestinal infection ; Italy ; emerging mycosis

* MDP and VDC contributed equally to this work

§ Present address. Dipartimento di Diagnostica e Sanità Pubblica, Università di Verona

^ Present address: Medicine Department, Division of Infectious Diseases, A Manzoni Hospital, ASST Lecco

Abstract

Background: Gastrointestinal basidiobolomycosis (GIB) is a rare mycosis affecting almost exclusively immunocompetent subjects

Methods: We describe a case of GIB caused by *Basidiobolus ranarum* in a 25-year-old Italian immunocompetent man resident in Ireland who presented a 2-month history of epigastric pain. Suspecting colon cancer he underwent a right hemicolectomy subsequently leading to a diagnosis of GIB by means of molecular biology. After surgery a 9-month therapy with itraconazole was employed with a good outcome. A review of medical literature regarding GIB cases published in the period 1964-2017 is presented.

Results: One-hundred and two cases of GIB were included in this analysis. The disease was observed predominantly in male gender (74.5%) and children (41.2%). Abdominal pain was the single most common complaint (86.3%) followed by fever (40.2%) and evidence of an abdominal mass (30.4%). Peripheral blood eosinophilia was detected in 85.7% of cases. Most of the patients were diagnosed in Saudi Arabia (37.2%) followed by USA (21.6%) and Iran (20.6%). Surgery plus antifungal therapy was employed in the majority of patients (77.5%). An unfavourable outcome was documented globally in 18.6% of patients

Conclusions: GIB seems to be an emerging intestinal mycosis among immunocompetent patients living in the Middle East and Arizona.

1. Introduction

Basidiobolus ranarum was initially described in 1886 as a fungus cultured from frogs and two years later cultured from their intestinal contents and excreta [1]. It was first isolated in 1955 from decayed leaves in the United States and subsequently from soil and decaying vegetation from throughout the world [2-5]. It is actually classified in the phylum Entomophthoromycota that includes one of the largest groups of early-diverging terrestrial fungi previously classified in the phylum Zygomycota (Table 1) [6,7]. *B. ranarum* belongs to the class Basidiobolomycetes which includes a single order and family and it is a commensal in the gut of amphibians (frogs, toads), fish, reptiles and insectivorous bats [7]. *B. haptosporus*, *B. heterosporos* and *B. meristosporos* have been considered in the past as synonyms of the species *B. ranarum* [8]. Human disease caused by *Basidiobolus* was first described as a skin and subcutaneous indolent and slowly progressing infection, affecting the limbs, trunk and buttocks of young males residing in tropical and subtropical regions [9-11]. The exact mode of transmission of the fungus has not yet been characterised but in the case of subcutaneous disease, it has been attributed to the more frequent habit (by males) of using decaying plant leaves as toilet paper after defecating in the open or otherwise via minor skin trauma and insect bites. However, it remains puzzling how the fungus is introduced into the host's gastrointestinal tract, thus resulting in gastrointestinal basidiobolomycosis (GIB). It has been suggested that ingestion of soil, animal faeces or food contaminated by either might be responsible, explaining the highest number of cases observed among children.

The first case of GIB was probably reported in 1964 as an autopsy diagnosis in a 6-year old children from Nigeria who had also subcutaneous lesions [4]. However, Brazilian authors were the first who recognised GIB as a distinct clinical entity affecting immunocompetent individuals [12].

Although considered an extremely rare disease, GIB seems to be an emerging fungal infection in Saudi Arabia, Iran, Iraq and Arizona in the United States of America. We report here a case of GIB observed in a young immunocompetent Italian patient together with a review of the literature.

2. Materials and methods

Definitions

We defined a confirmed case of GIB on the basis of either the characteristic histopathologic appearance of the fungus in tissue biopsy or from surgical specimens obtained from gastrointestinal organs (*i.e.*, stomach, small intestine, colon, rectum, liver, gallbladder, pancreas) or the isolation of *Basidiobolus ranarum* from such specimens or identification by molecular methods.

The PubMed and Scopus databases were searched for articles (in English, French, Spanish languages) published between 1964 and 2017 using the following combination of MESH terms:

basidiobolomycosis AND gastrointestinal; basidiobolomycosis AND abdominal infection;

Basidiobolus ranarum AND gastrointestinal infection; entomophthoromycosis AND gastrointestinal.

Articles were reviewed in detail by 2 of us (M.D.P. and V.D.C.) to determine whether cases met the inclusion criteria. Additional cases were identified by reviewing references. Several cases were reported more than once and duplicates were excluded.

3. Results

3.1 Case report

In March 2013, a 25-year-old Italian male was admitted to a specialized oncological institute in Milan, for a suspect bowel neoplasm. He had a history of epigastric and lower right abdominal pain over the last two months so he had done on February an US abdomen which showed a mass in the right lumbar-hypogastric region of 65 mm in transverse diameter with associated retroperitoneal lymph nodes. The patient was an otherwise healthy man with an unremarkable past medical history; he was living in Cork, Ireland, working as a cook in a hotel.

Physical examination showed no abnormalities except a palpable tender mass on the right lower quadrant; on laboratory investigations white blood cell count was $10.1 \times 10^9/L$ (normal value 4.4-11.3) with $0.99 \times 10^9/L$ eosinophils (normal value 0.04-0.4), hemoglobin level of 15.6 g/dL, normal liver function tests, electrolyte levels and creatinine levels. CT scan of the pelvis and lower abdomen showed diffuse circumferential wall thickening affecting distal ileal loop and cecum, narrowing of lumen and regional lymph node involvement (Figure 1a). Colonoscopy was performed, revealing a complete stricture of the ascending colon due to an ulcerated mass (Figure 1b). Biopsies were taken and histopathology showed granulomatous and necrotizing inflammation. Because of a clinical profile suggestive of malignancy with colonic obstruction a right hemicolectomy was done. At the histology examination there were areas of necrotizing inflammation with marked eosinophilic infiltrate and foreign body- type giant cell reaction; fungal hyphae were seen within some of the multinucleated giant cells and a presumptive diagnosis of intestinal zygomycosis was done by the pathologist.

The patient was referred to our Infectious diseases ward for further evaluation and management.

Upon reviewing the pathology material, the hyphae had few septa, were highlighted by the PAS and Grocott stains and surrounded by eosinophilic and hyaline material (Splendore-Höeppli phenomenon) (Figure 2). The identification of the fungus was established by DNA extraction from formalin-fixed paraffin embedded tissue and panfungal polymerase chain reaction (PCR)

amplification of 18S rRNA. Amplified fragment had 99% identity with *Basidiobolus ranarum* (13) (Figure 3). Because preoperative diagnosis was presumed to be malignant, no tissue was sent for culture. Pending molecular typing of fungus, the patient was started on liposomal amphotericin B at the dose of 5 mg/kg, 4 days later substituted with itraconazole *po* 200 mg BID because resistance and clinical failure with amphotericin B has been described.

Immunological deficiencies were excluded by additional investigations (lymphocyte subpopulations, HIV, HBV, HCV, immunoglobulins, C3 and C4, oxidative BURST, T-lymphocyte maturation study and CD11b expression on neutrophils and monocytes). Complete blood count, apart from eosinophilia (12% maximum), was normal as other laboratory results. US abdomen before discharge showed hepatosplenomegaly, normal ileal and colic loops without any mass. The patient was discharged in April with oral itraconazole 200 mg BID and regular follow-up was started.

After 3 months abdominal CT was negative. In January 2014 the patient repeated US abdomen, showing only splenomegaly, and laboratory tests (white blood cell count $7.4 \times 10^9/L$ with $0.23 \times 10^9/L$ eosinophils). He received itraconazole 200 mg x 2/daily for a total of 9 months; at one year follow up he is in good health without relapse of the disease.

3. 2 Review of the literature

Gastrointestinal basidiobolomycosis (GIB) has been considered an extremely rare disease with only six cases reported in the literature up to 1994 [4,12,14-16]. However, starting from 1995 a cluster of cases of GIB was described from Arizona with 19 patients (89 % resident in Arizona) identified between 1995 and 2009 at Mayo Clinic, Scottsdale (Arizona) [17-20]. Eight of these 19 patients had been described separately before being finally reviewed by Vikram et al. in 2012 together with other 25 cases observed outside the United States [21]. All the detailed published cases (with the exception of 12 cases reported in the review by Vikram and not singularly described) plus the one observed by us are summarised in table 2 [4,12,14-20, 22-62]. We noted that a further 18 pediatric cases of basidiobolomycosis were reported in 2017 but they are not included in the present review because of the lack of any detailed information regarding single cases [63]. Eleven cases were reported in a 36-year period (1964-2000; a mean of 0.3 cases/year) and 78 in the last seventeen years (2001-2017; a mean of 4.6 cases/year) with a 15.3-fold increase. Overall, we considered for the purpose of our review the forty-four cases previously reviewed by Vikram et al. in 2012 plus fifty-eight new cases (including our present observation) described in detail after 2008 [21] (Table 3). A male prevalence was observed (76/102, 74.5%) with a 3:1 ratio. All but one patient were immunocompetent [59]. The median age was 19 years (range 1-81 years) and 42 patients (41.2%) were children (age 1-13 years). The countries of residence in 79.4% of patients were only three: Saudi Arabia (37.2%), USA (21.6%) and Iran (20.6%) (Figure 4). Abdominal pain (86.3%) was the most common presenting symptom followed by weight loss (33.3%), abdominal distension (16.7%), vomiting (15.7%) and diarrhea (13.7%) (Table 3). Fever was reported only in 40.2% of patients and an abdominal mass was palpable in 30.4% of cases. Peripheral blood eosinophilia was detected in 85% of patients for whom this data was available. An initial misdiagnosis was made in 68 % of cases (68/102) with neoplasms and inflammatory bowel disease being the more frequently considered diagnosis (55.8%). In 32 cases (31.4%) the diagnosis was obtained by histopathology

plus culture and/or polymerase chain reaction (PCR), in 66 patients (64.7%) only by histopathology . In four cases the correct diagnosis was achieved only *post-mortem*. Overall, culture for *B. ranarum* was positive in 34/53 cases (64.2%). Identification by PCR was obtained in 5 cases. Colon-rectum were involved in 84.2% of cases. On histopathology the presence of fungal hyphae, granulomatous inflammation, eosinophilic infiltration together with the Splendore-Höeppli phenomenon observed in the gastrointestinal tract should be considered highly suggestive for *B. ranarum*. Overall 93/102 (91.2%) patients received an antifungal therapy Surgery plus antifungal treatment was employed in 79/102 (77.5%) of patients . Eleven patients received only antifungal treatment of which four died (36.4%). Overall death was observed in 18.6% of patients.

4. Discussion

Basidiobolus ranarum is an environmental filamentous fungus that belongs to the phylum Entomophthoromycota , class Basidiobolomycetes formerly designated as zygomycetes. Recent phylogenetic studies showed that Entomophthoromycota is a monophyletic lineage characterized by coenocytic vegetative cells, sporulation by production of infective conidia and production of zygospores capable of survival under unfavourable environmental conditions. *Basidiobolus* spp. form uninucleate cells with extremely large nuclei and had an haploid genome that has been estimated to be 10 times larger (350 Mb) than that of the average size of fungi [64]. The fungus grows at 30°C in 2-3 days with yellow-gray flat colonies but after 7-10 days colony become overgrown with mycelia as masses of zygospores.

After its initial description by Eidam in 1886 [1], *Basidiobolus ranarum* was subsequently cultured from intestinal contents of frogs [65] and several other species of amphibians and reptiles, from decaying plant material, from an insectivorous bat (*Rhinopoma hardwickei hardwickei*) in India and from the faeces of kangaroos in Australia. The disease initially associated with *B. ranarum* was described in Indonesia in 1956 by Joe *et al.* [9] as subcutaneous phycomycosis and subsequently the same presentation was identified in other areas of tropical and subtropical climate, especially from

Uganda, Nigeria and Indonesia. In 1964 the first case of gastrointestinal involvement was described in a 6-year old Nigerian boy at *postmortem* examination [4]. Gastrointestinal basidiobolomycosis (GIB) has been considered an extremely rare disease with only six cases reported up to 1999 [63].. Within the past 2 decades a 15-fold increase in cases of gastrointestinal infection by *B. ranarum* has been reported worldwide. Although most of the cases have been described in the Middle East (Saudi Arabia, Iran, Iraq, Kuwait, Oman, Qatar) [23-26,29,31-39,41-46,48-50,52-55,57,60,62] and the southwestern of United States (Arizona and Utah) [15,17-20,40,47,56], sporadic reports came from South America, Africa , Europe and the Indian Subcontinent [4,12,14,16,27,28,30,51, 59,PR] and no clear environmental risk factors have been identified. In the case-control study performed by Lyon et al. in Arizona, ranitidine use (OR 6.0) and a longer period of smoking (OR 2.1/additional 20 years of smoking) were both associated with the development of the disease [20]. It has been hypothesized that the decreased gastric acidity together with the alteration of white blood cells activity induced by smoking might contribute to the survival of ingested *B. ranarum*. However, rural environment and activities such as gardening and landscaping as well as ingestion of contaminated soil or fruits and vegetables seem to be associated with a higher risk of exposure to the infection [21]. Since *B. ranarum* usually involves immunocompetent subjects, factors associated with health history of the hosts are not helpful for the diagnosis that is therefore frequently delayed. Of the three patients reported in Europe [27,30, PR], only the one described here was diagnosed during life. However, at least in endemic areas, a higher awareness of GIB by clinicians might partially account for the increase in the number of cases reported in the last decades. As in previous cases, in our patient the route of acquisition of the disease remains unknown; however since *B. ranarum* can be found in soil and decaying vegetables, we hypothesized that the consumption of homebrew unpasteurized and unfiltered beer might have been the source of fungal ingestion and subsequent involvement of the intestine.

A preliminary misdiagnosis among patients with GIB was commonly reported in the literature, the most frequent being gastrointestinal malignancy and inflammatory bowel diseases

[17,22,30,33,34,36,37,41,42,56,61,62, PR], although a suspicion should be raised whenever fever and abdominal pain occur in young patients with gastrointestinal, abdominal mass or intestinal wall thickening in association with high eosinophilia.

Although a definite diagnosis can be obtained with culture [14,15,18,19,22-24,30,33,35,41,45,47,49-51,54,59,62], it was frequently missed in previous reports because of the lack of suspicion that made tissue specimens unavailable for culture purpose. Therefore, the diagnosis of gastrointestinal infection by *B. ranarum* was mainly obtained on histologic examination, which typical morphologic features include granulomatous inflammation and a diffuse eosinophilic infiltrate with thin walled branched hyphae surrounded by eosinophilic material (Splendore-Höeppli phenomenon) and sometimes zygozoospores (spherical bodies with foamy cytoplasm) [4,6,12,16,17,20,24,26-29,31-33,35-39,42-44,46,49,52,53,55,58,60,61]. The immunodiagnostic test such as immunodiffusion is not standardized yet, since it showed a high specificity but a controversial sensitivity [20]. Finally, since suitable specimens for culture purpose are often unavailable, molecular diagnosis from formalin fixed paraffin embedded tissue represents the optimal adjunctive diagnostic method to histology, as it showed a high specificity and high sensitivity [34,40,51,54,PR].

Treatment of GIB usually requires a combination of surgical and medical approach. Surgical resection of infected bowel tissues must be followed by itraconazole for at least 6 months to prevent recurrence. There are also a few cases described in the literature that showed a successful outcome with antifungal treatment alone [33-35, 42,56,61]. The role of amphotericin B has been overcome since resistance has been observed in more than 50% of cases [25]. Potassium iodide (KI) has been traditionally used for the treatment of subcutaneous basidiobolomycosis and more recently it was employed successfully in a single case report of a child with GIB [21,66,67]. However, as suggested by Bering et al., the absence of demonstrable *in vitro* activity of KI against *B. ranarum* coupled with several possible limitations (toxicity associated with high doses, lack of any standard prescription recommendation, available new azoles) do not recommend its use in GIB [68]. More

recently successful treatments with voriconazole [42,49,50,53-55,58,59] and posaconazole [40,48,50] have been reported. On the basis of the experience reported in the literature azoles should be considered the drugs of choice for GIB.

5. Conclusions

In conclusion, GIB should be suspected in patients complaining abdominal pain associated with gastrointestinal and/or colon mass who has concomitant peripheral eosinophilia especially if they come from the Middle-East or arid zone from USA. Moreover, the observation of the Splendore-Höeppli phenomenon (although not pathognomonic being associated with several microorganisms) [69] in the presence of zygomycetes in tissue samples from immunocompetent patients should raise the suspicion of basidiobolomycosis and confirmation by using molecular diagnosis should be sought through pathologists able to do it. Although some reports indicate successful outcome by using only medical therapy, surgery with resection of affected bowel segments associated with prolonged antifungal treatment should be advised. Itraconazole seems to be the best available treatment although other new azoles have also been successfully employed. The exact length of duration of antifungal therapy remains to be established.

References

- [1] Eidam E. *Basidiobolus*, eine neue Gattung der Entomophthoraceen. Beitrage Biol Pflanzen 1886;4:181-251.
- [2] Drechsler C. A southern basidiobolus forming many sporangia from globose and from elongated adhesive conidia. J Wash Acad Sci 1955;45:49-56.
- [3] Drechsler C. Supplementary developmental stages of *Basidiobolus ranarum* and *Basidiobolus haptosporus*. Mycologia 1956;655-76.
- [4] Edington GM. Phycomycosis in Ibadan, Western Nigeria. Trans R Soc Trop Med Hyg 1964; 58:242-45.
- [5] Clark, B. M. Epidemiology of phycomycosis. In G. E. W. Wolstenhome and R. Porter (ed.), Systemic mycoses. Little, Brown & Co., Boston, Mass, 1968: 179-192.
- [6] Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.
- [7] Gryganskyi AP, Humber RA, Smith ME, Hodge K, Huang B, Voigt K, et al. Phylogenetic lineages in Entomophthoromycota. Persoonia 2013;30:94-105.
- [8] Coremans-Pelseneer, J. Isolation of *Basidiobolus meristosporus* from natural sources. Mycopathol Mycol Appl 1973;49:173-76.
- [9] Joe LK, Eng NIT, Pohan A, van der Muillen H, Emmons CW. *Basidiobolus ranarum* as a cause of subcutaneous mycosis in Indonesia. Arch Dermatol 1956;74:378-383.
- [10] Burkitt DP, Wilson AMM, Jelliffe DB. Subcutaneous phycomycosis: a review of 31 cases in Uganda. Br Med J 1964;1:1669-72.
- [11] Mugerwa JW. Subcutaneous phycomycosis in Uganda. Br J Dermatol 1976; 94: 539-44.
- [12] Bittencourt AL, Ayala M, Ramos EAG. A new form of abdominal zygomycosis different from mucormycosis. Am J Trop Med Hyg 1979; 28:564-569.
- [13] El-Shabrawi MH, Kamal NM, Kaerger K, Voigt K. Diagnosis of gastrointestinal basidiobolomycosis: a mini-review. Mycoses. 2014;57 Suppl 3:138-43.

- [14] de Aguiar E, Moraes WC, Londero AT. Gastrointestinal entomophthoromycosis caused by *Basidiobolus haptosporus*. *Mycopathologia* 1980; 72:101-5.
- [15] Schmidt JH, Howard RJ, Chen JL, Pierson KK. First culture-proven gastrointestinal entomophthoromycosis in the United States: a case report and review of the literature. *Mycopathologia* 1986; 95:101-4.
- [16] Carvalho FA, de Macedo JL, Costa JN, Moraes MA. Entomofitomicose intestinal : relato de caso. *Rev Soc Brasil Med Tropical* 1997; 30:65-68.
- [17] Pasha TM, Leighton JA, Smilack JD, Heppell J, Colby TV, Kaufman L. Basidiobolomycosis: an unusual fungal infection mimicking inflammatory bowel disease. *Gastroenterology* 1997; 112:250-54.
- [18] Centers for Disease Control and Prevention. Gastrointestinal Basidiobolomycosis: Arizona. *MMWR Morb Mortal Wkly Rep* 1999;48:710-4
- [19] Zavasky D-M, Samowitz W, Loftus T, Segal H, Carroll K. Gastrointestinal zygomycotic infection caused by *Basidiobolus ranarum*: case report and review. *Clin Infect Dis* 1999; 28: 1244-48.
- [20] Lyon GM, Smilack JD, Komatsu KK, Pasha TM, Leighton JA, Guarner J, et al. Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. *Clin Infect Dis* 2001; 32:1448-55.
- [21] Vikram HR, Smilack JD, Leighton JA, Crowell MD, De Petris G. Emergence of gastrointestinal basidiobolomycosis in the United States, with a review of worldwide cases. *Clin Infect Dis* 2012; 54: 1685-91.
- [22] Khan ZU, Prakash B, Kapoor MM, Madda JP, Chandy R. Basidiobolomycosis of the rectum masquerading as Crohn's disease: case report and review. *Clin Infect Dis* 1998; 26: 521-523.

- [23] Khan ZU, Khoursheed M, Makar R, Al-Waheeb S, Al-Bader L, Al-Muzaini A, et al. *Basidiobolus ranarum* as an etiologic agent of gastrointestinal zygomycosis. J Clin Microbiol 2001; 39: 2360-63.
- [24] Al Jarie A, Al-Mohsen I, Al Jumaah S, Al Hazmi M, Al Zamil F, Al Zaharani M, et al. Pediatric gastrointestinal basidiobolomycosis. Pediatr Infect Dis J 2003; 22:1007-13.
- [25] Yusuf NW, Assaf HM, Rotowa NA. Invasive gastrointestinal *Basidiobolus ranarum* infection in an immunocompetent child. Pediatr Infect Dis J 2003; 22:281-2.
- [26] Azadeh B, McCarthy DO'B, Dalton A, Campbell F. Gastrointestinal zygomycosis: two case reports. Am J Surg Pathol 2004; 44:297-306.
- [27] Bigliuzzi C, Poletti V, Dell'Amore D, Saragoni L, Colby TV. Disseminated basidiobolomycosis in an immunocompetent woman. J Clin Microbiol 2004; 42: 1367-1369.
- [28] Vianna LM, de Lacerda MV, de Moraes MA. Case report of subcutaneous entomophthoromycosis with retroperitoneal invasion. Rev Soc Bras Med Trop.2005; 38:348-50.
- [29] Fahimizad A, Karimi A, Tabatabaei SR, Zadeh MG. Gastrointestinal basidiobolomycosis as a rare etiology of bowel obstruction. Turk J Med Sci 2006; 36: 239-241.
- [30] van de Berk GE, Noorduyn LA, van Ketel RJ, van Leeuwen J, Bemelman WA, Prins JM. A fatal pseudo-tumor: disseminated basidiobolomycosis. BMC Infect Dis 2006; 6:140.
- [31] Hussein MR, Musalam AO, Assiry MH, Eid RA, El Motawa A-M, Gamel A-M. Histological and ultrastructural features of gastrointestinal basidiobolomycosis. Mycol Res 2007;111:926-30.
- [32] Geramizadeh B, Modjalal M, Nabai S, Banana A, Forootan HR, Hooshdaran F, et al. Gastrointestinal zygomycosis: a report of three cases. Mycopathologia 2007;164:35-38.
- [33] Nemenqani D, Yaqoob N, Khoja H, Al Saif O, Amra NK, Amr SS. Gastrointestinal basidiobolomycosis. An unusual fungal infection mimicking colon cancer. Arch Pathol Lab Med 2009;133:1938-42.

- [34] El-Shabrawi MHF, Kamal NM, Jouini R, Al-Harbi A, Voigt K, Al-Malki T. Gastrointestinal basidiobolomycosis: an emerging fungal infection causing bowel perforation in a child. *J Med Microbiol* 2011;60:1395-1402.
- [35] Al Jarie A, Al Azraki T, Al Mohsen I, Al Jumaah S, Almutawa A, Mohd Fahim Y, et al. Basidiobolomycosis: case series. *J Mycol Med* 2011; 21:37-45
- [36] Rabie ME, El Hakeem I, Al-Shraim M, Saad Al Skini M, Jamil S. Basidiobolomycosis of the colon masquerading as stenotic colon cancer. *Case Rep Surgery* 2011; ID685460.
- [37] Saadah OI, Farouq MF, Daajani NA, Kamal JS, Ghanem AT. Gastrointestinal basidiobolomycosis in a child: an unusual fungal infection mimicking fistulising Crohn's disease. *J Crohn's Colitis* 2012, 6:368-72.
- [38] Arjmand R, Karimi A, Sanaei Dashti A, Kadivar M. A child with intestinal basidiobolomycosis. *Iran J Med Sci* 2012; 37:134-6.
- [39] Geramizadeh B, Foroughi R, Keshtkar-Jahromi M, Malek-Hosseini SA, Alborzi A. Gastrointestinal basidiobolomycosis, an emerging infection in the immunocompetent host: a report of 14 patients. *J Med Mycol* 2012; 61:1770-4.
- [40] Rose SR, Lindsley MD, Hurst SF, Paddock CD, Damodaran T, Bennett J. Gastrointestinal basidiobolomycosis treated with posaconazole. *Med Mycol Case Rep* 2013;2:11-14.
- [41] Al Asmi MM, Faqeehi HY, Alshahrani DA, Al-Hussaini AA. A case of pediatric gastrointestinal basidiobolomycosis mimicking Crohn's disease. *Saudi Med J* 2013;34:1068-72.
- [42] Al Saleem K, Al-Mehaidib A, Banemai M, Bin-Huassain I, Faqih M, Al Mehmadi A. Gastrointestinal basidiobolomycosis: mimicking Crohn's disease case report and review of the literature. *Ann Saudi Med* 2013;33: 500-504.
- [43] Zahir ST, Sharahjin NS, Kargar S. Basidiobolomycosis a mysterious fungal infection mimic small intestinal and colonic tumour with renal insufficiency and ominous outcome. *BMJ Case Rep* 2013; doi10.1136/bcr-2013-200244.

- [44] Hassan HA, Majid RA, Rashid NG, Nuradeen BE, Abdulkarim QH, Hawramy TA, et al. Eosinophilic granulomatous gastrointestinal and hepatic abscess attributable to basidiobolomycosis and fascioliasis. A simultaneous emergence in Iraqui Kurdistan. *BMC Infect Dis* 2013;13:91.
- [45] Alshehri AH, Alshehri A, Bawahab MA, Al-Humayed S, Nabrawi K, Alamri FS, et al. Basidiobolomycosis: an emerging fungal infection of the gastrointestinal tract in adults. *Am J Infect Dis* 2013;9:1-6.
- [46] Al-Qahtani SM, Alsuheel AM, Shati AA, Mirza NI, Al-Qahtani AA, Al-Hanshani AA, et al. Case reports: gastrointestinal basidiobolomycosis in children. *Curr Pediatr Res* 2013;7:1-6.
- [47] Pandit V, Rhee P, Aziz H, Jehangir Q, Friese R, Joseph B. Perforated appendicitis with gastrointestinal basidiobolomycosis: a rare finding. *Surg Infect* 2014, 15:339-42.
- [48] Zabolinejad N, Naseri A, Davoudi Y, Joudi M, Aelami MH. Colonic basidiobolomycosis in a child: report of a culture – proven case. *Int J Infect Dis.* 2014 ;22:41-3
- [49] Alahmadi R, Sayadi H, Badreddine H, Linijawawi A, Baatrup G, Al-Maghrabi J. Gastrointestinal basidiobolomycosis, the experience of a tertiary care hospital in the western region of Saudi Arabia and report of four new cases. *Life Sci J* 2014;11:344-352.
- [50] Al-Maani AS, Paul G, Jardani A, Nayar M, Al-Lawati F, Al-Baluishi S, Hussain IB. Gastrointestinal basidiobolomycosis. First case report from Oman and literature review. *Sultan Qaboos University Med J* 2014;14:e241-44.
- [51] Cazorla A, Grenouillet F, Piton G, Faure E, Delabrousse E, Mathieu P, et al. Une forme gastro-intestinale de basidiobolomycose d'évolution fatale. *Ann Pathol* 2014;34:228-32.
- [52] Ejtehadi F, Anushiravani A, Bananzadeh A, Geramizadeh B. Gastrointestinal basidiobolomycosis accompanied by liver involvement: a case report. *Iran Red Crescent Med J* 2014;16:e14109.

- [53] Albaradi BA, Babiker AM, Al-Qahtani HS. Successful treatment of gastrointestinal basidiobolomycosis with voriconazole without surgical intervention. *J Trop Pediatr* 2014; 60:476-9.
- [54] Alhuraiji A, Alqaraawi A, Alaraj A, Al-Abdely HM, Alrajhi AA. Chronic abdominal pain and intestinal obstruction in a 24-year-old woman. *Clin Infect Dis* 2014;58:990;1035.
- [55] Al-Naemi AQ, Ali Khan L, Al-Naemi I, Amin K, Ali Athlawy Y, Awad A, et al. A case report of gastrointestinal basidiobolomycosis treated with voriconazole. A rare emerging entity. *Medicine* 2015;94:e1430.
- [56] Ilyas MI, Jordan SA, Nfonsam V. Fungal inflammatory masses masquerading as colorectal cancer: a case report. *BMC Res Notes* 2015;8:32.
- [57] Geramizadeh B, Sanai Dashti A, Kadivar MR, Kord S. Isolated hepatic basidiobolomycosis in a 2-year old girl: the first case report. *Hepat Mon* 2015;15:e30117.
- [58] Mandhan P, Hassan KO, Samaan SM, Ali MJ. Visceral basidiobolomycosis: an overlooked infection in immunocompetent children. *Afr J Paediatr Surg* 2015;12:193-6.
- [59] Sethi P, Balakrishnan D, Surendran S, Umer Mohamed Z. Fulminant zygomycosis of graft liver following liver transplantation. *BMJ Case Rep* 2016; pii: bcr2015214097. doi:10.1136/bcr-2015-214097.
- [60] Ageel HI, Arishi HM, Kamli AA, Hussein AM, Bhavanarushi S. Unusual presentation of Gastrointestinal Basidiobolomycosis in a 7-year-old Child – Case Report. *Am J Med Case Rep* 2017;5:131-4.
- [61] Almoosa Z, Alsuhaibani M, Aidandan S, Alshahrani D. Pediatric gastrointestinal basidiobolomycosis mimicking malignancy. *Med Mycol Case Rep* 2017;18:31-33.
- [62] Zekavat OR, Abdalkarimi B, Pouladfar G, Fathpour G, Mokhtari M, Shakibazad N. Colonic basidiobolomycosis with liver involvement masquerading as gastrointestinal lymphoma: a case report and literature review. *Rev Soc Bras Med Trop* 2017;50:712-4.

- [63] Shreef K, Saleem M, Saeedd MA, Eissa M. Gastrointestinal Basidiobolomycosis: An Emerging, and A Confusing, Disease in Children (A Multicenter Experience). Eur J Pediatr Surg 2018;28:194-9.
- [64] Henk DA, Fisher MC. The gut fungus *Basidiobolus ranarum* has a large genome and different copy numbers of putatively functionally redundant elongation factor genes. PLoS One. 2012;7(2):e31268.
- [65] Sutherland-Campbell H. An attempt to prove the etiologic factor in an epidemic among orange workers. Arch Dermatol Syphilol 1929; 19:233–254.
- [66] Sanaei Dashti A, Nasimfar A, Khorami HH, Pouladfar G, Kadivar MR, Geramizadeh B, et al. Gastro-intestinal basidiobolomycosis in a 2-year-old boy: dramatic response to potassium iodide. Paediatr Int Child Health 2018, 38:150-3.
- [67] Vilela R, Mendoza L. Human pathogenic Entomophthorales. Clin Microbiol Rev 2018;31:e00014-18.
- [68] Bering J, Mafi N, Vikram HR. Basidiobolomycosis: an unusual, mysterious, and emerging endemic fungal infection. Paediatr Int Child Health 2018;38:81-4.
- [69] Gopinath D. Splendore-Höeppli phenomenon. I Oral Maxillofac Pathol 2018;22:161-2.

Figure legends

Figure 1. Computed tomography scan showing a mass in the ascending colon

Figure 2. (A,B) Histopathologic section of colon showing granulomatous inflammation of the colonic wall with prominent eosinophilic infiltrate with a transversely cut hypha (black arrow) surrounded by an intensely eosinophilic cuff (Splendore-Hoeppli phenomenon, white arrow) (Hematoxylin-eosin x100 and x400). (C,D) Detailed view of large fungal hypha surrounded by eosinophilic Splendore-Hoeppli material and numerous eosinophils and polymorphonuclear leucocytes (E&E x 400).

Figure 3. Panfungal PCR that amplifies the internal transcriber space (ITS) region of the rDNA gene performed on multiple samples (F,B1,C3,A2) of paraffin-embedded tissue specimens from different areas of the mass. Sequenced amplicons gave a 99% matching with *Basidiobolus ranarum* (One μ g and 100 nanograms, respectively were tested).

Figure 4. Geographical distribution of cases of 101 gastrointestinal basidiobolomycosis reported worldwide (for one case the country was unknown).

Table 1- Taxonomic classification of *Basidiobolus ranarum* within Entomophthoromycota phylum

Taxonomy	Previous	Actual
Phylum	Zygomycota	Entomophthoromycota
Class	Zygomycetes	Basidiobolomycetes
Order	Entomophthorales	Basidiobolales
Family	Basidiobolaceae	Basidiobolaceae
Species	<i>Basidiobolus</i>	<i>B. ranarum</i> ; <i>B. haptosporus</i> ; <i>B. heterosporus</i> ; <i>B. magnus</i> ; <i>B. meristoporus</i> ; <i>B. microsporus</i> (plus undescribed new genera)

Table 2. Chronological summary of 89 case reports of gastrointestinal basidiobolomycosis

Patient/Reference	Year observation/ Publication	Country	Age/sex	Clinical presentation	Leukocyte/Eosinophils/ Splendore-Hoepli phenomenon	Organ involvement	Diagnosis	Therapy	Outcome
1/4	NR/1964	Nigeria	6/M	Subcutaneous lesions (penis, scrotum, perineum); bloody diarrhea	NR/NR/NR	I; C; R; bladder	Post-mortem (histopathology)	Colostomy; antibiotics	Death
2/12	1977/1979	Brazil	13/M	Abdominal pain, fever, weakness, anorexia	NR/16%/Yes	S; D; L; P; C; BT	Post-mortem (histopathology)	Laparotomy	Death 11 days after surgery
3/12	NR/1979	Brazil	60/M	Abdominal pain	NR/NR/Yes	S; C	Histopathology; culture negative	Gastrectomy & hemicolectomy; AmB	Cured
4/14	1979/1980	Brazil	4/M	Fever, abdominal pain, sweats, diarrhea	13,500 μ L/26%/Yes	S; C	Histopathology; culture (<i>Basidiobolus haptosporus</i>)	Surgery	Death 12 days after surgery (peritonitis)
5/15	NR/1986	USA	69/M	Fever, abdominal pain, nausea, constipation, vomiting, right lower quadrant mass	19,500 μ L/6%/Yes	I; Ce; C	Histopathology/culture (<i>B.haptosporus/ranarum</i>)	Surgery/AmB	Death 4 weeks after laparotomy
6/16	1989/1997	Brazil	19/M	Fever, abdominal mass, weight loss, sweats	12,600 μ L/11%/Yes	I; Ce; C:	Histopathology	Surgery/	NR
7/17	1994/1997	USA	49/F	Abdominal and rectal pain, constipation followed by mucus and bloody diarrhea	23,400 μ L/NR)/Yes	C; R	Histopathology/serology	Surgery/Itraconazole (5 months)	Alive after 13 months
8/22	1996/1998	Kuwait (Bangladesh)	30/M	Rectal bleeding, constipation, rectal mass	18-22,000 μ L/NR/NR	R	Histopathology/Culture (<i>B.ranarum</i>)/serology	Surgery/AmB (3weeks)+ketocozazole (1 week)	Lost to follow-up
9/18	1998/1999	USA	37/F	Abdominal pain	26,400 μ L/10%/NR	S; P	Histopathology	Surgery/Itraconazole (9.5 months)	Cured
10/ 18	1998/1999	USA	59/M	Abdominal pain, mucus, colonic obstruction	12,100 μ L/6%/NR	C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole	Cured
11/19	1997/1999	USA	57/M	Abdominal pain, anorexia, fatigue, constipation	16,400 μ L/8%/ Yes	S ; C ; R; ureter	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/AmB (1week)+ itraconazole (11 months) ; terbinafine 2 months	Cured
12/20	1996/2001	USA	46/M	Abdominal pain, abdominal mass	NR/NR/Yes	I ; Ce ; appendix ; retroperitoneum	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole (19 months)	Alive (31 months ; 12 months after itraconazole withdrawal)
13/20	1998/2001	USA	52/M	Abdominal pain	12,800 μ L/14,3%/Yes	C	Histopathology/ culture negative/serology	Surgery/Itraconazole (10 months)	Alive 4 months after itraconazole withdrawal)
14/20	1999/2001	USA	59/M	Abdominal pain, constipation	NR/NR/NR	Ce; C	Histopathology/Culture not done	Surgery/Itraconazole (10 months)	Alive
15/23	1999/2001	Kuwait	41/M	Fever, abdominal pain,	NR/NR/Yes	Ce; C	Histopathology/Culture	Surgery/LAmB	Lost to follow-

		(Indian patient)		abdominal mass			from urine (<i>B.ranarum</i>)/serology	(4 weeks)	up
16/24	2000/2003	Saudi Arabia	12/M	Fever, abdominal pain, abdominal mass, scrotal swelling	16,000 μ L/15%/Yes	I; Ce; C; L; BT	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole (> 24 months)	Alive
17/ 24	2001/2003	Saudi Arabia	12/M	Fever, abdominal pain	11,000 μ L/20%/Yes	I; Ce; C	Histopathology	Surgery/AmB than itraconazole (12 months)	Alive
18/ 24	2001/2003	Saudi Arabia	9/M	Fever, abdominal pain	17,800 μ L/19.8%/NR	Ce; C; R	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole (10 months)	Alive
19/ 24	2002/2003	Saudi Arabia	4/M	Fever, abdominal pain, hepatomegaly	30,000 μ L/30%/NR	L; intestine	Histopathology/Culture (<i>B.ranarum</i>) from liver biopsy	AmB than itraconazole (> 12 months)	Alive
20/ 24	2001/2003	Saudi Arabia	3/M	Fever, abdominal pain, heaptomegaly, ascites	24,500 μ L/18%/Yes	L	Histopathology/Culture (<i>B.ranarum</i>) from liver biopsy	AmB+5Flu	Death of MOF 2 days after admission
21/ 24	2000/2003	Saudi Arabia	7/M	Fever, abdominal pain, abdominal distension, hepatosplenomegaly	16,900 μ L/17%/Yes	R; D; BT	Histopathology (liver biopsy)	AmB+itraconazole (12 months)	Death (massive GI bleeding)
22/25	NR/2003	Saudi Arabia	12/M	Fever, abdominal pain, anorexia, weight loss, vomiting, constipation	17,900 μ L/20%/Yes	I; Ce; C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole (10 months)	Alive
23/26	NR/2004	Iran	45/M	Abdominal pain	NR/NR/Yes	Ce; L	Histopathology	Surgery/Ketoconazole+cotrimoxazole (4 weeks)	Alive
24/27	NR/2004	Italy	40/F	Fever, subcutaneous lesions	28,320 μ L/30%/Yes	L; P; S; M; lung; spleen; kidneys; uterus	Post-mortem (histopathology)	-	Death due shock and pulmonary failure
25/28	1990/2005	Brazil	43/M	Fever, abdominal pain, vomiting, weight loss	10,800 μ L/NR/Yes	P	Histopathology	Surgery/ketoconazole (35 days)	Follow-up not stated
26/29	NR/2006	Iran	1.5/M	Fever, abdominal pain, diarrhea, hematochezia	NR/Yes/Yes	R	Histopathology	Surgery/AmB (1 week) than itraconazole (9 months)	Alive
27/30	NR/2006	The Netherlands	61/M	Abdominal pain, constipation	NR/27.7%/Yes	C; L; gallbladder	Histopathology; culture post-mortem <i>B.ranarum</i>	Cholangiodrain/AmB	Death due to MOF few days after start antifungal therapy
28/31	NR/2007	Saudi Arabia	13/M	Abdominal pain, tenderness	NR/NR/Yes	C	Histopathology/Culture negative	Surgery/Itraconazole	Alive
29/32	2002-2007/2007	Iran	18/M	Abdominal pain, constipation	12,000 μ L/8%/Yes	I	Histopathology	Surgery/Itraconazole	Alive (7 years)
30 / 32	2002-2007/2007	Iran	2.5/M	Abdominal pain, constipation, rectal bleeding	26,800 μ L/10%/Yes	C	Histopathology	Surgery/Itraconazole	Alive (10 years)
31 / 32	2002/2007	Iran	2/M	Abdominal pain, distension, ascites	29,400 μ L/ 16%/Yes	C	Histopathology	Surgery/Itraconazole	Alive (7 years)
32 /33	2000/2009	Saudi Arabia	77/M	Abdominal pain, abdominal mass, weight loss, rectal bleeding	Normal/NR/Yes	Ce; C	Histopathology	Surgery/Itraconazole (2 weeks)	Lost to follow-up

33/33	2001/2009	Saudi Arabia	19/F	Fever, abdominal pain, weight loss	NR/NR/Yes	Ce; C	Histopathology/ Culture (<i>B. ranarum</i>)	LAmB+itraconazole; ketoconazole (4 years)	Alive (4 years)
34 /33	NR/2009	Saudi Arabia	20/M	Abdominal mass, weight loss, ematochezia	NR/NR/Yes	C	Histopathology/ Culture (<i>B. ranarum</i>)	Voriconazole	Alive
35/34	NR/2011	Saudi Arabia	10/M	Fever, abdominal pain, vomiting	12,200 μ L/17%/Yes	Ce;	Histopathology/ PCR (<i>B.ranarum</i>)	Itraconazole (12 months)	Alive (1 year)
36/35	2003/2011	Saudi Arabia	6/M	Fever, abdominal pain, abdominal mass	32,700 μ L/11%/NR	Ce; C; L	Histopathology/ Culture (<i>B.ranarum</i>)	AmB than itraconazole	Alive (2 years)
37/ 35	2003/2011	Saudi Arabia	13/F	Fever, abdominal pain	14,500 μ L/18%/Yes	I; Ce; C	Histopathology	Surgery/AmB+itraconazole (12 months)	Alive (2 years)
38/ 35	2003/2011	Saudi Arabia	8/F	Fever, anorexia, abdominal distension, weight loss	13,800 μ L/4%/Yes	P; L; BT	Histopathology	Surgery/AmB than itraconazole (18 months)	Alive 2,5 years)
39/36	NR/2011	Saudi Arabia	25/F	Abdominal pain, weight loss, nausea, rectal bleeding	12,800 μ L/NR/Yes	C	Histopathology	Surgery/Itraconazole	Alive
40 /37	2010/2012	Saudi Arabia	2/M	Fever, abdominal pain, abdominal mass, vomiting , diarrhea	14,000 μ L/19%/Yes	I; Ce; C	Histopathology	AmB than voriconazole (12 months)	Alive (1 year)
41/38	NR/2012	Iran	12/M	Fever, abdominal pain, vomiting, bloody diarrhea	28,100 μ L/16%/Yes	C	Histopathology	Surgery/AmB (1 week) than posaconazole	Follow-up not stated
42/39	2008-2012/2012	Iran	1.3/F	Abdominal pain, distension	23,000 μ L/17%/Yes	S; C; M	Histopathology/Culture negative	Surgery/AmB than itraconazole	Death due to disseminated disease
43/ 39	2008-2012/2012	Iran	5/M	Abdominal pain, weight loss	21,300 μ L/20%/Yes	C	Histopathology/Culture negative	Surgery/AmB than itraconazole	Alive (8 months)
44 / 39	2008-2012/2012	Iran	5/M	Abdominal pain	16,100 μ L/10%/Yes	C	Histopathology/Culture negative	Surgery/AmB than itraconazole	Alive (3 years)
45 / 39	2008-2012/2012	Iran	2/M	Abdominal pain, diarrhea	17,400 μ L/20%/Yes	I; C	Histopathology/Culture negative	Surgery/AmB than itraconazole	Alive (6 months)
46 / 39	2008-2012/2012	Iran	16/M	Abdominal pain	11,500 μ L/14%/Yes	C	Histopathology/Culture negative	Surgery/AmB than itraconazole	Alive (2 years)
47/ 39	2008-2012/2012	Iran	1.3/M	Abdominal pain, diarrhea	18,200 μ L/8%/Yes	S; I; C; M	Histopathology/Culture negative	Surgery/AmB than itraconazole	Death due to disseminated disease (1,5 months)
48 / 39	2008-2012/2012	Iran	1.1/M	Abdominal pain, bloody stool	23,000 μ L/16%/Yes	C	Histopathology/Culture negative	Surgery/AmB than itraconazole	Alive (1 year)
49/ 39	2008-2012/2012	Iran	37/M	Abdominal pain	20,000 μ L/10%/Yes	C	Histopathology/Culture negative	Surgery/Itraconazole	Alive (6 months)
50 / 39	2008-2012/2012	Iran	28/M	Abdominal pain	14,000 μ L/10%/Yes	C	Histopathology/Culture negative	Surgery/Itraconazole	Alive (2 years)
51 / 39	2008-2012/2012	Iran	52/M	Abdominal pain, vomiting, diarrhea	17,000 μ L/15%/Yes	C	Histopathology/Culture negative	Surgery/Itraconazole	Alive (6 months)
52 / 39	2008-2012/2012	Iran	42/F	Abdominal pain	17,000 μ L/15.9%/Yes	I; C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole	Alive (1 year)
53 /40	NR/2013	USA	67/M	Abdominal pain	NR/NR/Yes	I	Histopathology/ PCR (<i>B.ranarum</i>)	Surgery/Ureteral stent/Fluconazol	Alive (2 years)

								e (several months); posaconazole 600 (1 year)	
54 /41	NR/2013	Saudi Arabia	4/M	Fever, abdominal pain, vomiting, weight loss	17,000 μ L/13.6%/Yes	I; Ce; C	Histopathology/ Culture (<i>B.ranarum</i>)	Surgery/Voriconazole (12 months)	Alive (1 year)
55 /42	NR/2013	Saudi Arabia	5/M	Fever, abdominal pain, bloody diarrhea, anorexia, weight loss	15,600 μ L/15%/Yes	C	Histopathology/Culture negative	Voriconazole (6 months)	Alive (6 months)
56 /43	NR/2013	Iran	12/M	Fever, abdominal pain , hematuria	14,500 μ L/No/Yes	I; C	Histopathology	Surgery/Itraconazole + AmB (2 weeks) then itraconazole	Death for septic shock
57/44	2010/2013	Iraq	48/M	Fever, abdominal pain, weight loss	NR/12%/Yes	Ce; C; L	Histopathology	Surgery/Itraconazole (6 months)	Alive (1 year)
58 /44	2010/2013	Iraq	1.5/M	Fever, abdominal pain, weight loss, abdominal mass	NR/29%/Yes	NR	Histopathology	AmB	Death for intestinal perforation
59 / 44	2010/2013	Iraq	59/M	Fever, abdominal pain, weight loss, abdominal mass	NR/No/Yes	Ce	Histopathology	Surgery/Itraconazole (6 months)	Alive (> 1 year)
60 / 44	2012/2013	Iraq	53/M	Fever, abdominal pain, weight loss,	NR/NT/Yes	Ce; C	Histopathology	Surgery/Itraconazole (6 months)	Alive (10 months)
61/ 44	2012/2013	Iraq	39/M	Fever, weight loss, cough, sore throat	NR/9%/Yes	O; C	Histopathology	Surgery/Itraconazole (7 months)	Alive (7 months)
62 / 44	2012/2013	Iraq	1.5/M	Fever, abdominal pain, abdominal mass, weight loss	NR/21%/Yes	Ce; C	Histopathology	Surgery/Itraconazole (4 months)	Alive (4 months)
63 /45	NR/2013	Saudi Arabia	24/M	Fever, abdominal pain, weight loss, diarrhea	14,400 μ L/22%/NR	I; Ce; C	Histopathology/ Culture (<i>B.ranarum</i>)	Surgery/Itraconazole (12 months)	Alive (1 year)
64 / 45	NR/2013	Saudi Arabia	21/F	Fever, abdominal pain, diarrhea alternate with constipation, weight loss	7,100 μ L/No/NR	Ce; C; R	Histopathology/Culture (<i>B.ranarum</i>)	Steroid/Itraconazole	Death for HC-associated infection
65 / 45	NR/2013	Saudi Arabia	72/M	Fever, abdominal mass	15,280 μ L/No/NR	Ce; C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole	Death for bowel perforation and ARDS, septic shock (32 days post-surgery)
66 / 45	NR/2013	Saudi Arabia	19/M	Fever, abdominal pain, abdominal mass	22,100 μ L/6.65%/NR	Ce; C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole	Death for HC-associated infection
67 /46	2009-2012/2013	Saudi Arabia	12/F	Fever, abdominal pain, constipation	17,600 μ L/35%/Yes	I; Ce	Histopathology	Surgery/Itraconazole	Alive
68 / 46	2009-2012/2013	Saudi Arabia	1.5/M	Fever, hepatomegaly	24,520 μ L/10.2%/Yes	L	Histopathology	Surgery/Itraconazole	Death for ARDS after few days
69/ 46	2009-2012/2013	Saudi Arabia	9/F	Abdominal pain, constipation, vomiting	17,800 μ L/14%/Yes	C	Histopathology	Surgery/Itraconazole (8 months)	Alive (8 months)
70/47	NR/2013	USA	34/F	Abdominal pain, constipation, vomiting, weight loss	13,000 μ L/16.9%/NR	I; Ce	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Itraconazole+ LAmB (6 weeks)	Alive
71/48	NR/2013	Iran	3/M	Abdominal pain, abdominal mass	12,500 μ L/6%/Yes	C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery/Posaconazole (3 months)	Alive (15 months)

								then itraconazole (12 months)	
72/49	2001/2014	Saudi Arabia	43/M	Abdominal pain, weight loss	15,000 μ L/27%/Yes	Ce; C; L	Histopathology/Culture /(<i>B.ranarum</i>) from liver	Surgery/Itraconazole (7 months)	Alive (7 months)
73 / 49	2005/2014	Saudi Arabia	20/F	Abdominal pain, abdominal mass	NR/NR/NR	C	Histopathology/Culture (<i>B.ranarum</i>)	Surgery	Death
74 / 49	2008/2014	Saudi Arabia	63/M	Abdominal pain, weight loss	12,400 μ L/14%/Yes	I; C	Histopathology/Culture negative	Surgery/Voriconazole (12 months)	Alive (12 months)
75 / 49	2011/2014	Saudi Arabia	20/F	Rectal bleeding	14,000 μ L/20%/Yes	R	Histopathology	Drainage/Terbinafine+voriconazole (12 months)	Alive (12 months)
76 /50	2012/2014	Oman	5/F	Abdominal pain, nausea, vomiting, low grade fever	14,200 μ L/50%/Yes	Ce, C	Histopathology/Culture positive (<i>Basidiobolus</i> spp.)	Surgery/LAmB+ posaconazole then voriconazole (4 months)	Alive (4 months)
77/51	2014	Mali/France	55/M	Abdominal pain	NR/NR/Yes	I;C	Histopathology /PCR (<i>B. ranarum</i>)	Antituberculous treatment	Death (2 months)
78/52	2012/2014	Iran	41/F	Abdominal pain, weight loss, nausea, fever	14,300 μ L/12%/Yes	I; Ce; L	Histopathology	Surgery/Itraconazole (4 months)	Alive (12 months)
79/53	2014	Saudi Arabia	11/M	Abdominal pain	NR/Yes/Yes	C	Histopathology	Voriconazole (12 months)	Alive (12 months after discontinuing therapy)
80/54	2014	Saudi Arabia	24/F	Abdominal pain, nausea, vomiting, abdominal distension, constipation	7,070 μ L/14,6%/Yes	L; C; P	Histopathology/Culture & PCR positive (<i>B. ranarum</i>)	Voriconazole	Alive (2 months)
81/55	2014/2015	Saudi Arabia	36/M	Suspected appendicitis	16,000 μ L/18%/Yes	Ce	Histopathology	Surgery/Itraconazole (4 months); voriconazole	Alive
82/56	/2015	USA (Arizona)	56/M	Abdominal pain, rectal pain	NR/NR/NR	Ce; R	Histopathology	Itraconazole (12 months)	Alive (12 months)
83 /57	2015	Iran	2/F	Abdominal pain	11-12,000 μ L/25-35%/Yes	L	Histopathology	Surgery/AmB (1 month)	Alive (9 months)
84/58	2015	Qatar	4/F	Abdominal pain, rectal bleeding, weight loss,	NR/NR/Yes	C	Histopathology	Surgery/Voriconazole (12 months)	Alive (12 months)
85 /59	NR/2016	India	44/M	Liver transplant patient; rise in transaminases	NR/NR/NR	L	Culture (<i>B. ranarum</i>) of liver aspirate	LAmB; itraconazole, caspofungin, posaconazole	Death (MOF and bacterial sepsis)
86/60	NR/2017	Saudi Arabia	7/M	Abdominal pain, rectal bleeding, weight loss, fever	10,030 μ L/15.9%/Yes	R	Histopathology	Surgery/Voriconazole (12 months)	Alive (12 months)
87/61	NR/2017	Saudi Arabia	7/F	Abdominal pain, constipation, fever, palpable mass	19,000 μ L(3000)/Yes	C ; R	Histopathology	Voriconazole (9 months)	Alive (10 months)
88/62	NR/2017	Iran	5/M	Abdominal pain, fever, anorexia, weight loss, vomiting	23,900 μ L/11%/Yes	Ce; C; I	Histopathology/Culture (<i>Basidiobolus</i> spp.)	Amphotericin B (2 months); posaconazole (6 months)	Alive (6 months)

89/ PR	2013/2018	Italy/Ireland	25/M	Abdominal pain	10,100 μ L/10%/Yes	I; Ce; C	Histopathology/PCR (<i>B.ranarum</i>)	Surgery/Itraconazole (8 months)	Alive (13 months)
--------	-----------	---------------	------	----------------	------------------------	----------	--	---------------------------------	-------------------

Twelve patients reported with no details in the review by Vikram et al. are not described in the table. D, duodenum; E, esophagus; S, stomach; I, ileum; Ce, cecum; C, colon; R, rectum; O, oropharynx; BT, biliary tract; L, liver; P, peritoneum; M, mesentery; AmB, amphotericin B; LAmB, liposomal amphotericin B

ACCEPTED MANUSCRIPT


Table 3. Clinical manifestations, laboratory studies , sites of involvement and preliminary diagnosis in 102 patients with gastrointestinal basidiobolomycosis





Characteristic	Patients, proportion (%) –Review by Vikram (1964-2008) ²¹	Patients, proportion (%) - Present review (2009-2017)	Total
Number of pts	44 (43.1%)	58 (56.9%)	102
Age, years, median	37.3 (2-81)	17.5 (1.1-77)	19 (1.1-81)
Male sex	36 (81.8%)	40 (68.9%)	76 (74.5%)
Country of residence			
Brazil	4 (9%)	-	4 (3.9%)
Iran	4 (9%)	17 (29.3%)	21 (20.6%)
Iraq	-	6 (10.3%)	6 (5.9%)
Saudi Arabia	11 (25%)	27 (46.5%)	38 (37.2%)
USA	19 (43%)	3 (5.2%)	22 (21.6%)
Other	6 (13.6%) #	5 (8.6%) §	11 (10.8%)
Signs and symptoms			
Abdominal pain	37 (84%)	51 (87.9%)	88 (86.3%)
Abdominal mass	19 (43%)	12 (20.7%)	31 (30.4%)
Constipation	17 (39%)	6 (10.3%)	23 (22.5%)
Abdominal distension	14 (32%)	3 (5.2%)	17 (16.7%)
Fever	14 (32%)	27 (46.5%)	41 (40.2%)
Weight loss	12 (27%)	22 (37.9%)	34 (33.3%)
Diarrhea	7 (16%)	7 (12.1%)	14 (13.7%)
Vomiting	6 (14%)	10 (17.2%)	16 (15.7%)
Lower gastrointestinal bleeding	6 (14%)	9 (15.5%)	15 (14.7%)
Hepatomegaly	5 (11%)	1 (1.7%)	6 (5.9%)
Laboratory test results*			
Peripheral blood eosinophilia	26/34 (76%)	43/47 (91.5%)	69/81 (85.2%)
Positive <i>Basidiobolus</i> serology	8/16 (50%)	-	8/16 (50%)

Growth of <i>Basidiobolus</i> in culture	17/24 (71%)	17/29 (58.6%)	34/53 (64.2%)
Characteristic histopathology	43/44 (98%)	57/57 (100%)	100/101 (99%)
Organ involvement			
Stomach	6 (14%)	2 (3.5%)	8 (7.9%)
Small bowel	16 (36%)	16 (28.1%)	32 (31.7%)
Colon/rectum	36 (82%)	50 (87.7%)	85 (84.2%)
Liver/gallbladder	13 (30%)	10 (17.5%)	22 (21.8%)
Pancreas	-	3 (5.3%)	3 (2.9%)
Preliminary diagnosis			
Malignancy	19 (43%)	6 (10.9%)	25 (24.7%)
Inflammatory bowel disease	7 (16%)	6 (10.9%)	13 (12.9%)
Diverticulitis	5 (11%)	-	5 (4.9%)
Appendicitis	3 (7%)	5 (9.1%)	8 (7.9%)
Lymphoma	2 (5%)	4 (7.3%)	6 (5.9%)
Gastrointestinal tuberculosis	2 (5%)	3 (5.5%)	5 (4.9%)
Ameboma	-	1 (1.8%)	1 (0.9%)
Schistosomiasis	-	1 (1.8%)	1 (0.9%)
Other	4 (9%)	-	4 (3.9%)
Antifungal treatment	37/43 (86%)	56/58 (96.5%)	93/101 (92.1%)
Itraconazole	26/37 (70.3%)	24/56 (42.9%)	50/93 (53.8%)
Amphotericin B	8/37 (21.6%)	2/56 (3.6%)	10/93 (10.7%)
Voriconazole	2/37 (5.4%)	10/56 (17.9%)**	12/93 (12.9%)
Posaconazole	0/37 (0%)	2/56 (3.6%)	2/93 (2.2%)
Amphotericin B plus (or followed by azole)	3/37 (8.1%)	18/56 (32.1%)	21/93 (22.6%)
Outcome	8 (18%) died	11 (18.9%) died	19 (18.6%) died

* Laboratory data are reported only when available. # One patient each from :Nigeria, India, Bangladesh, Italy, The Netherlands; for 1 country was unknown; § One patient each from: India, Ireland, Mali, Oman, Qatar: ** In one case associated with terbinafine







PanF ITS

314113p F

-1

314113p B1

-1

c-

314113p C3

-1

314113p A2

-1

c-

C+

C+

